Versant Venture Management, LLC Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0001560009

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth Tilt how tags are computed

Q2 2026 · 8 positions · Total reported value $162.61M · Top-10 concentration 100.0% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 12.5% · 0 new · 1 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -44.9% · vs SPY -47.0% · Prev Value $162.61M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -13.5% · vs SPY -15.6% · Latest Value $109.10M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q2 2026 13F filing, Versant Venture Management, LLC disclosed 8 equity positions with a combined reported value of $162.61M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt.

The largest disclosed positions as of Q2 2026 were GLUE ($76.97M), IPSC ($29.81M), JBIO ($22.04M). By sector, the heaviest allocations are Health Care 100.0%.

Versus the prior quarter, Versant Venture Management, LLC opened 0 new positions, trimmed 1 and fully exited 0, a turnover rate of 12.5% of positions. The portfolio's overlap with the prior quarter was 100% of names.

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

Insider Transactions (Form 4)

Latest Versant Venture Management, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Versant Venture Management, LLC is an SEC-registered 13F filer. As of Q2 2026 it reported 8 US equity positions with a combined value of $162.61M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 8 positions · $162.61M reported value (Q2 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: GLUE (MONTE ROSA THERAPEUTICS INC) at 47.3%
  • Average position size: $20.33M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 1 reduced
  • 7 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The fund appears to maintain a conservative stance, with a focus on health care sector investments, indicating a belief in the stability and potential growth within the industry. 2. Key Moves: - No New Positions: The fund did not add any new positions this quarter. - Reduction in JBIO: There was a significant reduction in the position of JBIO, which suggests a cautious approach to the company's performance or a change in the fund's investment strategy. - No Changes in Other Holdings: All other holdings remained the same in terms of shares and weight, indicating a passive stance with no active rebalancing. 3. Portfolio Structure: - Passive Approach: The lack of changes in holdings suggests a passive management style, where the fund holds positions for the long term rather than actively trading. - Sector Bias: The portfolio is heavily biased towards the health care sector, which aligns with the current trend in venture capital investments. - Risk Appetite: The conservative nature of the rebalancing, with no additions and significant reduction in one position, indicates a moderate risk appetite. 4. Per-Holding One-Liner: - GLUE: MONTE ROSA THERAPEUTICS - Biotechnology company focusing on developing therapies for rare diseases. - IPSC: CENTURY THERAPEUTICS INC - Specializes in developing therapies for neurological disorders. - JBIO: JADE BIOSCIENCES INC - Focuses on cancer immunotherapy. - LENZ: LENZ THERAPEUTICS INC - Develops therapies for rare genetic disorders. - CTNM: CONTINEUM THERAPEUTICS INC CL - Works on treatments for metabolic disorders. - CRSP: CRISPR THERAPEUTICS AG - Uses CRISPR technology for genetic engineering. - SKYE: SKYE BIOSCIENCE INC - Engaged in the development of therapies for cancer. - TPST: TEMPEST THERAPEUTICS INC - Focuses on the development of novel cancer therapies. - Unverified: None. 5. One-Sentence Style Summary: Versant Venture Management maintained a passive health care sector focus with a conservative rebalancing approach, reflecting a cautious but stable investment strategy.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 100.0%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 3.18M $76.97M 47.34%
47.34%
Hold
2 12.17M $29.81M 18.33%
18.33%
Hold
3 991.78K $22.04M 13.55%
13.55%
Reduce
4 2.66M $15.09M 9.28%
9.28%
Hold
5 542.63K $8.89M 5.47%
5.47%
Hold
6 148.83K $8.12M 4.99%
4.99%
Hold
7 2.01M $1.39M 0.86%
0.86%
Hold
8 269.77K $299.45K 0.18%
0.18%
Hold

FAQ

What did Versant Venture Management, LLC buy in 2026-Q2?

In its 2026-Q2 13F filing, Versant Venture Management, LLC reported 8 equity positions worth $162.61M in aggregate; its largest disclosed positions were GLUE ($76.97M), IPSC ($29.81M), JBIO ($22.04M).

How large is Versant Venture Management, LLC's portfolio?

Versant Venture Management, LLC reported $162.61M of long equity holdings across 8 positions as of 2026-Q2. Top-10 holdings account for 100.0% of reported value.

What is Versant Venture Management, LLC's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/versant-venture-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →